The achievement demonstrates reader interest above 93% of published research articles over the past year, 'therefore, this shows exceptional interest in our work and bodes well for our future, both clinical and academic,' according to Dr
The article, published in the peer reviewed journal, Scientific Reports, is entitled, 'A formulation of pancreatic proenzymes provides potent anti-tumor efficacy: A pilot study focused on pancreatic and ovarian cancer.' From the publishers of Nature, it is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences. Published data from the Company's R&D program were conducted with Universities of
Of note in the publication is the evaluation of clinical efficacy of a suppository formulation of pancreatic proenzymes in the context of a
For pancreatic cancer in the US, almost 50,000 new cases were estimated, which resulted in more than 40,000 deaths, in 2020, according to the
For ovarian cancer in the US, 19,880 new cancer cases (2015 - 2019) and 12,810 related deaths (2016 - 2020) were estimated, according to the
'Since the launch of targeted and immuno-oncology drugs, patients are keenly aware of emerging less toxic and better treatments compared to standard treatment options, which can prolong life, but not at the expense of great toxicity,' said Mr.
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include pancreatic, ovarian, kidney, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. Orphan Drug Designation status of PRP has been granted from the
About
The Company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the planned studies and market projections described above and the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary business partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the
Contact:
Email: irteam@propanc.com
Tel: +61-3-9882-0780
(C) 2023 Electronic News Publishing, source